Inotuzumab ozogamicin
Checked 2026-09-09
Relapsed or refractory CD22-positive B-ALL
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
| 0.8 mg/m² day 1, 0.5 mg/m² days 8 and 15 (cycle 1); 0.5 mg/m² all doses once in remission | IV | D1, 8, 15 |
Cycles
up to 6 (2-3 if proceeding to transplant)
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- Veno-occlusive disease after transplant: limit to 2 cycles and avoid dual-alkylator conditioning.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Blinatumomab
B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)
every 42 days × 2
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days
Imatinib
Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST
every 28 days